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Antidepressants are frequently prescribed in ﬁrst episode schizophrenia (FES) patients for negative symptoms or
for subsyndromal depressive symptoms, but therapeutic beneﬁt has not been established, despite evidence of ef-
ﬁcacy in later-stage schizophrenia.We conducted a 52week, placebo-controlled add-on trial of citalopram in pa-
tients with FES who did not meet criteria for major depression to determine whethermaintenance therapy with
citalopram would improve outcomes by preventing or improving negative and depressive symptoms. Primary
outcomeswere negative symptomsmeasured by the Scale for Assessment of Negative Symptoms and depressive
symptoms measured by the Calgary Depression Scale for Schizophrenia; both were analyzed by an intent-to-
treat, mixed effects, area-under-the-curve analysis to assess the cumulative effects of symptom improvement
and symptomprevention over a one-year period. Ninety-ﬁve patients were randomized and 52 (54%) completed
the trial. Negative symptoms were reduced with citalopram compared to placebo (p = .04); the effect size of
citalopram versus placebo was 0.32 for participants with a duration of untreated psychosis (DUP) of
b18weeks (median split) and 0.52 with a DUP N18weeks. Rates of new-onset depression did not differ between
groups; improvement in depressive symptoms was greater with placebo than citalopram (p= .02). Sexual side
effects were more common with citalopram, but overall treatment-emergent side effects were not increased
compared to placebo. In conclusion, citaloprammay reduce levels of negative symptoms, particularly in patients
with longer DUP, but we found no evidence of beneﬁt for subsyndromal depressive symptoms.
© 2019 Published by Elsevier B.V.
1. Introduction
Specialized treatment programs that integrate psychosocial inter-
ventions with optimal medication management have improved out-
comes in ﬁrst episode schizophrenia (FES) (Correll et al., 2018; Dixon
et al., 2018) although negative symptoms, subsyndromal depressive
symptoms, and functional impairment often persist. Antidepressants
are not recommended for maintenance treatment of FES patients in
the absence of major depression (Robinson et al., 2015), despite evi-
dence of beneﬁt for negative symptoms in people with later-stage
illness (Helfer et al., 2016). However, antidepressants are commonly
prescribed in non-depressed patients with FES; for example, of FES pa-
tients who were taking medication at the time of enrollment in the Re-
covery after an Initial Schizophrenia Episode Early Treatment Program
(RAISE-ETP) study, 36% were prescribed an antidepressant in the ab-
sence of a recent history of major depression (Robinson et al., 2015).
To our knowledge, only three placebo-controlled studies of antidepres-
sants have been reported in FES patients; all 3 studies were conducted
in non-depressed patients andwere designed to examinewhether anti-
depressants might reverse antipsychotic-associated weight gain. In the
ﬁrst study, an 8 week trial of ﬂuoxetine added to olanzapine in 30 FES
participants, ﬂuoxetine provided no beneﬁt for negative or depressive
symptoms compared to the addition of placebo and was associated
with less improvement of psychotic symptoms (Poyurovsky et al.,
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2002), whereas in 2 trials of 6 weeks duration in which reboxetine was
added to olanzapine (n = 20 and n = 59), reboxetine was associated
with improvement in depressive symptoms but had no effect on posi-
tive or negative symptoms compared to placebo (Poyurovsky et al.,
2003; Poyurovsky et al., 2007).
Duration of untreated psychosis (DUP)may be an importantmoder-
ator of therapeutic outcome in FES. In the RAISE-ETP trial, only FES pa-
tients with shorter DUP (identiﬁed by a median split) beneﬁted from
enhanced psychosocial and pharmacologic treatment compared to
treatment as usual (Kane et al., 2016). We recently found that DUP
interacted with several biomarkers, including brain-derived neuro-
trophic factor (BDNF) genotype, to predict hippocampal atrophy in
FES patients, which in turn predicted poor response of negative symp-
toms to treatment with second generation antipsychotics (Goff et al.,
2018). This ﬁnding suggests that BDNF may play a protective role
against the adverse effects of DUP on hippocampal integrity and on as-
sociated negative symptoms. Antidepressants increase levels of BDNF
(De Foubert et al., 2004) and hippocampal neurogenesis (Malberg
et al., 2000) and hence may play a neuroprotective role in FES. The
BDNF Val66Met polymorphism, which modulates BDNF release, was
found to predict response of depressive symptoms to citalopram (Choi
et al., 2006). We therefore predicted that citalopramwould exert a neu-
roprotective effect over the ﬁrst 12 months of illness that would be as-
sociated with improved negative and depressive symptoms.
2. Methods
2.1.1. Study design
We conducted a four-site, 52 week, randomized placebo-controlled
trial of citalopram added to clinician-determined second generation an-
tipsychoticmedication in individualswith FESwhodid notmeet criteria
for major depression to determine whether citalopram would improve
clinical course over a 12 month period by improving or preventing de-
pressive and negative symptoms. The primary outcome at the time of
initial protocol development was depression measured by the Calgary
Depression Scale for Schizophrenia (CDSS) (Addington et al., 1996).
Based on the results of our work and others since then (Goff et al.,
2018; Helfer et al., 2016), negative symptoms measured by the Scale
for the Assessment of Negative Symptoms (SANS) modiﬁed by elimina-
tion of itemsmeasuring inattention and inappropriate affect (Blanchard
and Cohen, 2006) was elevated from a secondary outcome to a co-
primary outcome and DUP was added as a potential predictor of re-
sponse. Because the study was not powered for two co-primary out-
comes, we maintained the threshold for signiﬁcance at p = .05 and
hence each primary outcome is exploratory. Because the withholding
of antidepressant from FES patients with major depression in a
placebo-controlled design was considered unethical, individuals with
greater than moderate depression at screening were excluded and the
focus was on response of mild-to-moderate depressive symptoms and
on the prevention of new or worsening depressive symptoms using an
area-under-the-curve (AUC) analysis. Other outcomes included preven-
tion of relapse deﬁned by hospitalization, increased frequency of visits,
or a 25% increase in Brief Psychiatric Rating Scale (BPRS) total score, sui-
cidal ideation measured by the International Suicide Prevention Trial
Scale for Suicidal Ideation (ISSI) (Alphs et al., 2004), cognitionmeasured
by the MATRICS Consensus Cognitive Battery (MCCB) composite score
(Nuechterlein and Green, 2006), and quality of life measured by the
Henrichs Carpenter Quality of LifeScale (QLS) (Heinrichs et al., 1984).
2.1.2. Study setting and participants
The protocol for the Depression and Citalopram in First Episode Re-
covery (DECIFER) Study (ClinicalTrials.gov: NCT01041274), was ap-
proved by IRBs at the four participating sites: New York University
Medical Center, the Massachusetts General Hospital, Shanghai Mental
Health Center, and the Second Xiangya Hospital of Central South Uni-
versity, Changsha; all participants provided written informed consent.
A sample size of 100 participants was estimated to provide 80% power
to detect a clinically-signiﬁcant effect size of 0.6 for citalopram versus
placebo with a 10% attrition rate and 76% power with a 40% attrition
rate assuming a constant hazard of loss to follow-up and 80% of treat-
ment efﬁcacy achieved by week 8. Enrollment began in January 2010
and was completed in December 2014. Eligibility criteria included a
ﬁrst episode of schizophrenia or schizophreniform disorder based on
the Structured Clinical Interview for DSM IV-TR (SCID) (First, 1994),
ages 15–40, onset of psychosis before age 35, cumulative antipsychotic
treatment for at least 4 weeks and fewer than 24 weeks, no antidepres-
sant treatmentwithin fourweeks, a score b7 on the CDSS, (6 is a thresh-
old for probablemajor depression) (Addington et al., 2014), and a score
b3 (moderate) on the Clinical Global Impression Scale for Severity of
Suicidality (CGI-SS) (Lindenmayer et al., 2003). In addition, participants
had to have been free of substance abuse (except cannabis) for
3months, not have unstablemedical illness, and have a QTC b500msec.
2.1.3. Screening and assessments
A researchpsychiatrist reviewedpsychiatric andmedical history and
performed a physical exam, including EKG, routine screening labs, urine
toxicology screen and pregnancy test. DUP was estimated based on his-
tory provided by the participant and by family members and was de-
ﬁned as the number of weeks elapsed since the onset of at least one
persistent psychotic symptom of moderate or greater severity prior to
initiation of antipsychotic medication. Symptoms and side effects
were assessed weekly for the ﬁrst 4 weeks, then every 4 weeks, with
the BPRS, SANS, CDSS, ISS, QLS, and the Systematic Assessment for
Treatment-Emergent Events (SAFTEE) (Levine and Schooler, 1986).
Cognition was assessed at baseline and weeks 26 and 48 with the
MCCB. Medication adherence was rated at every visit according to par-
ticipant self-report using the Brief Adherence Rating Scale (BARS)
(Byerly et al., 2008). Raters at all sites were trained in-person on all rat-
ing scales and in the administration of theMCCB andmet inter-rater re-
liability criteria on three videotaped interviews for the BPRS, SANS and
CDSS. Raters were required to score within one point on each item and
tomaintain an inter-rater correlation of r N 0.8 with the “gold standard”
total scores. Ratings of videotaped interviews with the BPRS, SANS and
CDSS were reviewed by conference call every 3 months and in-person
trainings were repeated annually to maintain inter-rater reliability
and proﬁciency in the administration of the MCCB. In addition, struc-
tural MRI scans were acquired at baseline, 24 weeks and 48 weeks; re-
sults will be reported separately.
2.1.4. Randomization and masking
Participants remained on their clinician-determined second genera-
tion antipsychotic and were randomized to add-on citalopram or pla-
cebo in a 1:1 ratio stratiﬁed by site. Within each stratum, the
sequence of treatment assignments was constructed by a statistician
using permuted random blocks with variable block sizes and study
drug and placebo were prepared in identical capsules and labelled by
a research pharmacist. All other research personnel remained blinded
until the end of the study.
2.1.5. Study drug
Citalopramwas initiated at a dose of 20mg once daily and increased
after one week to a target dose of 40 mg if tolerated. Dose adjustment
within a range of 10–40 mg daily was allowed during the trial based
on clinical assessment of side effects. Subjects were assessed by a psy-
chiatrist every week for the ﬁrst four weeks and then every two
weeks thereafter.
2.1.6. Psychoeducation
All participants received 16 sessions of weekly, individual
psychoeducation and relapse prevention planning followed by 8
monthly sessions. The intervention was provided by a doctoral level
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clinician with extensive experience treating individuals with ﬁrst epi-
sode psychosis.
2.1.7. Cognitive–behavioral therapy (CBT)
Participants who scored 3 (moderate suicidality) on the CGI-SS or 7
or greater on the CDSS at any point during the trial were treated with a
standard 12 session CBT approach to depression (Padesky and
Greenberger, 1995). Participants who continued to meet these criteria
after 4 weeks or who scored a 4 (severe) or higher on the CGI-SS or
10 or greater (severe) on the CDSS were dropped from double-blind
treatment and could be openly prescribed an antidepressant.
2.1.8. Statistical analysis
The primary analyses tested the differential effect of citalopram ver-
sus placebo on depressive and negative symptoms using an intent-to-
treat linear mixed model of CDSS and SANS with AUC as the primary
outcome measures (eAppendix 1). The model included ﬁxed terms for
the treatment × visit interaction, with visit treated as a categorical var-
iable. A spatial-power covariance structure indexed by time between
visits was used to account for intra-subject correlations. The model
was ﬁtted using data from all available visits, and AUC was estimated
and tested by the trapezoidal rule, using a linear contrast and Wald
test. The same modeling strategy was applied to secondary outcomes,
when applicable.
In order to address the large, nonrandom attrition rate, the linear
mixed model with AUC analysis of observed data was repeated with
multiple imputation for the SANS total score. The sequence of informa-
tion used for imputation was: country (CHINA/USA), baseline results,
DUP, treatment arm and all post-baseline visit results sorted by visit. Fif-
teen imputed data sets were used for multiple imputation analyses.
Multiple imputation could not be used for analysis of the CDSS due to
a highly skewed distribution bounded by 0.
In order to explore potential effect modiﬁers (predictors of re-
sponse), a mixed effect model incorporating time trajectory was devel-
oped (eAppendix 2). Log scale of time (visit in weeks) was used in
addition to linear time scale in order to capture the non-linear time tra-
jectory. Linear scale time, log scale time, and three-way interaction be-
tween treatment arm, log scaled time and effect modiﬁer was
included as a predictor,which captures the effectmodiﬁcation activities.
Subject-level random linear time and log scale time were included in
the model, and the two random effects were assumed to be correlated.
The same spatial-power covariance structure used in the AUC analy-
sis was applied to allow additional correlations in residuals. To esti-
mate effect sizes, a last observation carried forward imputation was
carried out for all subjects with at least one post-baseline SANS mea-
surement and the change from baseline between treatment groups
compared by a two-sample t-test. All analyses were performed
using SAS version 9.3.
3. Results
One hundred twenty-nine participants were screened, 95 were ran-
domized (49 to citalopram and 46 to placebo), 73 completed assess-
ments at 6 months and 52 completed 12 month assessments (Fig. 1).
Completion rates did not differ between placebo (59%) and citalopram
(51%) groups. The mean daily dose of citalopram was 35.8 [8.2] mg
and of placebo was 36.3 [7.9] mg; adherence rates were 89.3% and
92.4% respectively. The mean antipsychotic dose in chlorpromazine
equivalents was 374 [179] mg/d (eTables 1 & 2). Participants assigned
to citalopramdid not differ at baseline fromparticipants assigned to pla-
cebo (Table 1), whereas completers had lower baseline total scores on
the SANS and BPRS and scored higher on the MCCS compared to non-
completers (Table 1).
3.1. Outcomes
The mixed effects AUC analysis revealed a signiﬁcant reduction in
ratings of depression (CDSS) in the placebo group compared to the
citalopram group (p = .02) (Table 2, Fig. 2). “Remission” rates deﬁned
as a week 24 CDSS score ≤ 1 did not differ between citalopram (27/37;
73%) and placebo (25/35; 71%) (p= .88). Three (6.1%) of the citalopram
group and 4 (8.7%) of the placebo group scored ≥7 on the CDSS during
the course of the trial (p = .63).
Themixed effects AUC analysis using observed data revealed a trend
for greater reduction in the SANS with citalopram compared to placebo
(p = .05) (Fig. 3) and a signiﬁcant reduction when multiple imputed
values were used for missing data (p= .04). Among the four SANS sub-
scales, only the avolition subscale was signiﬁcantly improved with
citalopram versus placebo (p = .002). Change from baseline in total
score on the QLS, the BPRS total score, the BPRS psychosis subscale
and the composite score of theMCCB did not differ between treatments
(Table 2). Eight relapse events occurred in 6 (12.2%) of the citalopram
group and 2 events occurred in 2 (4.3%) of the placebo group (p =
.27) (eTable 3).
3.2. Moderators of response
Based on the mixed effect model incorporating time trajectory, DUP
was signiﬁcantly associated with response of SANS at 52 weeks in the
placebo group (p = .03) but not in the citalopram group (p = .65)
such that shorter DUP predicted greater placebo response. The esti-
mated effect size of citalopram versus placebo on response of SANS
total was 0.32 for participants with a DUP of b18 weeks (median split)
and 0.52 for participants with a DUP N18 weeks. Higher baseline SANS
total scores based on a median split were associated with a greater dif-
ference in SANS response between treatment groups, favoring
citalopram (eTable 4). Baseline antipsychotic dose was negatively cor-
related with the reduction in the CDSS but was not signiﬁcantly associ-
ated with reduction in SANS scores (eTable 5).
3.3. Tolerability
Three participants withdrew from study due to side effects; two
placebo-treated participants due to weight gain and one citalopram-
treated participant due to blurry vision. The mean total number of
treatment-emergent side effects per participant rated asmild or greater
was 2.3 [1.8] in the citalopramgroup vs. 4.8 [3.4] in the placebo group (p
= .05). Side effects that were reported by N5% of participants and that
occurred more frequently in citalopram-treated participants included
loss of sexual interest, problems with sexual arousal, and delayed or ab-
sent orgasm (eTable 6).
4. Discussion
The citalopram group exhibited less improvement in depressive
symptoms compared to placebo, but the difference was small and de-
creased over time and the mean level of depressive symptoms at base-
line was mild. In addition, because only 9% of the placebo group
developed clinically-signiﬁcant depression over the course of the
52 week trial, statistical power to assess efﬁcacy for the prevention of
depressive episodes was very limited. Studies of individuals with
later-stage schizophrenia suggest that antidepressants are more effec-
tive for prominent and persistent depression than for mild or recent-
onset depressive symptoms (Helfer et al., 2016) and in a recent meta-
analysis only negative symptoms and not depression in individuals
with schizophrenia improved with antidepressant (Galling et al.,
2018). Two studies in FES patients found antidepressant beneﬁt for
the norepinephrine reuptake inhibitor, reboxetine (Poyurovsky et al.,
2007; Poyurovsky et al., 2003), raising the question of whether norad-
renergic agents might be more effective than citalopram. Superiority
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of reboxetine over SSRIs for depression was not found, however, in a
meta-analysis of antidepressant trials that included both FES and
chronic schizophrenia patients (Helfer et al., 2016). In the RAISE-ETP
study, antidepressants were not prescribed for subsyndromal depres-
sive symptoms in the enhanced treatment group. The enhanced treat-
ment group thus received fewer antidepressants than the treatment-
as-usual group, yet the enhanced treatment group had a greater reduc-
tion in depressive symptoms (Kane et al., 2016). While our results do
not support a role for citalopram formild ormoderate depressive symp-
toms in FES or for the prevention of more severe depressive episodes,
the role of antidepressants for more severe depression in FES requires
further study.
We did detect a therapeutic beneﬁt of citalopam for negative symp-
toms; this effect was on the cusp of signiﬁcance (p= .05) with the pre-
speciﬁed AUC analysis and achieved signiﬁcance (p= .04)whenwe re-
peated the AUC analysis with multiple imputation, which may better
model missing data due to the nonrandom, high rate of attrition
(Rubin, 1996). However, because we did not correct for multiple com-
parisons, this ﬁnding must be considered exploratory. The improve-
ment in negative symptoms was restricted to the avolition/apathy
subscale of the SANS. Avolition previously has been found to be the
Fig. 1. Consort diagram.
Table 1
Baseline characteristic of participants.
All randomized participants - baseline All completers vs. non-completers - baseline
Placebo Citalopram Test statistic Non-completers Completers Test statistic
N M (SD) N M (SD) t/χ2(df) p value N M (SD) N M (SD) t/χ2(df) p value
Age 45 23.69 (4.63) 49 23.2 (5.09) t(92) = 0.482 .63 43 23.65 (5.08) 51 23.25 (4.69) t(92) = 0.393 .67
Race
White (%) 46 13 (28.3) 49 16 (32.7) χ2(8) = 1.87 .60 44 13 (29.5) 51 16 (31.4) χ2(8) = 8.05 .04
Black 8 (17.4) 4 (8.2) 10 (22.7) 2 (3.9)
Asian 23 (50.0) 27 (55.1) 19 (43.2) 31 (60.8)
Other 2 (4.3) 2 (4.1) 2 (4.5) 2 (3.9)
Women, no. (%) 46 18 (39.1) 49 17 (34.7) χ2(4) = 3.149 .53 44 14 (31.8) 51 21 (41.2) χ2(4) = 3.85 .43
Education 45 12.44 (2.50) 49 12.71 (2.43) t(92) =−0.53 .60 43 12.51 (2.41) 51 12.65 (2.51) t(93) =−0.92 .36
Parental education 37 12.00 (3.34) 42 11.55 (3.65) t(77) = 0.572 .57 32 11.38 (3.49) 47 12.02 (3.50) t(77) =−0.806 .42
DUP (weeks) 42 29.36 (39.79) 45 53.71 (90.06) t(61.4) =−1.65 .10 38 40.50 (69.80) 49 43.08 (72.78) t(71) =−0.167 .87
BPRS total score 45 37.96 (9.26) 46 39.0 (11.49) t(89) =−0.477 .64 40 41.12 (11.62) 51 36.41 (8.92) t(89) = 2.19 .03
SANS total score 45 18.91 (12.08) 46 21.37 (14.25) t(89) =−0.887 .38 40 23.40 (14.36) 51 17.61 (11.74) t(89) = 2.12 .04
CDSS total score 45 2.58 (2.99) 46 1.83 (1.79) t(89) = 1.46 .15 40 2.37 (2.44) 51 2.06 (2.52) t(89) = 0.60 .55
QLS total score 46 75.85 (23.19) 49 71.53 (25.95) t(93) = 0.853 .40 44 68.41 (25.46) 51 78.12 (23.17) t(93) =−1.95 .06
MCCB composite 44 32.14 (16.26) 48 34.23 (12.97) t(90) =−0.685 .50 43 29.09 (14.01) 49 36.86 (14.25) t(90) =−2.63 .01
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strongest predictor of functional outcomes in ﬁrst episode schizophre-
nia patients at 12month follow-up (Chang et al., 2016). Because depres-
sive symptom ratings were low at baseline and improved more with
placebo than citalopram, it is likely that citalopram's beneﬁt for negative
symptomswas a primary effect and not secondary to an antidepressant
response. Response of negative symptoms did correlate at a trend level
(p = .09) with response of psychotic symptoms at week 52, although
response of psychotic symptoms did not differ between treatment
groups (Table 2; eTable 7).
The beneﬁt of citalopram over placebo for negative symptoms was
greater in participants with long DUP. The effect size of response to
citalopram versus placebo in participants with a DUP less than the me-
dian split of 18 weeks was 0.32 versus an effect size of 0.52 in partici-
pants with a longer DUP. This ﬁnding reﬂects a DUP effect on placebo
response and not on citalopram response; participants with long DUPs
did not respond to placebo but did respond to citalopram, whereas
participants with short DUPs responded similarly to both placebo and
citalopram. In the RAISE-ETP study, superior response to the
NAVIGATE treatment program compared to treatment as usual was ob-
served in participants with a shorter DUP only (Kane et al., 2016). Like
the psychosocial interventions in NAVIGATE, the frequent staff interac-
tions and weekly individualized psychoeducational sessions in the
DECIFER trial created a relatively enhanced psychosocial experience
for some participants that may have contributed to the placebo re-
sponse. Recent evidence suggests that antidepressants may act in part
by increasing plasticity, thereby facilitating brain reorganization in re-
sponse to enriched environmental stimulation (Castren, 2013). It is pos-
sible that patients with longer DUPmay lack the plasticity to respond to
enhanced environmental stimulation and may beneﬁt from a combina-
tion of an antidepressant and a rehabilitation program.
Citalopram was well tolerated, with side effects limited to sexual
complaints. Sexual dysfunction is common in schizophrenia, possibly
related to both the illness and to antipsychotic medication, and can ad-
versely affect quality of life and treatment adherence (de Boer et al.,
2015; Drake et al., 2015) and so the increased risk of sexual side effects
with supplemental SSRI treatment should be closelymonitored. The ad-
dition of antidepressants to antipsychotics in individuals with schizo-
phrenia has been well tolerated in previous controlled add-on trials
(Galling et al., 2018; Helfer et al., 2016) and was associated with re-
duced mortality by suicide in a large registry-based case linkage study
(Tiihonen et al., 2012). However, two previous studies reported an ap-
parent inhibition of antipsychotic response associated with early anti-
depressant treatment (Kramer et al., 1989; Poyurovsky et al., 2002).
We did not observe a worsening in psychosis, although participants in
the DECIFER trial had been stabilized on antipsychotic prior to initiating
citalopram. Citalopramwas associatedwith an increase in relapse (odds
ratio = 3.0) but, due to the low frequencies of this event (12% vs 4.3%),
the conﬁdence intervals for the odds ratio were quite wide [0.51–32.4]
and the difference was not statistically signiﬁcant. It should be noted
that citalopramwas selected for the DECIFER trial because it does not af-
fect metabolism of antipsychotic drugs and participants were carefully
screened to minimize the risk of adverse cardiac effects. Citalopram
has been linked to cardiac arrhythmia at daily doses above 40 mg, al-
though the clinical risk remains uncertain (Vieweg et al., 2012).
Table 2
Change from baseline in efﬁcacy outcomes.
Differencea Standard
error
t (df) p-Value
Outcome
Calgary Depression Scale
(CDSS)
−0.7048 0.3027 −2.33
(912)
.02
Quality of Life Scale (QLS) −4.0537 3.3806 −1.20
(520)
.23
MCCB Composite Score 0.4960 1.5647 0.32 (31) .75
BPRS Total Score 0.7894 1.6042 0.49 (640) .62
BPRS Psychosis Subscale Score 0.0754 0.8161 0.09 (641) .93
SANS total score 3.3046 1.7042 1.94 (704) .05
SANS subscales
SANS Affective Flattening
Subscale
0.6464 0.8762 0.74 (706) .46
SANS Alogia Subscale 0.3436 0.3838 0.90 (706) .37
SANS Avolition Subscale 1.6873 0.4542 3.71 (706) .002
SANS Anhedonia Subscale 0.4925 0.5655 0.87 (706) .38
a Difference is calculated as placebo group mean – citalopram group mean. The differ-
ence is estimated using the AUC under a mixed effect model. The estimate of each differ-
ence is a weekly average over the 52 weeks of study period. Negative values indicate
decrease from baseline.
Fig. 2. Effect of citalopram vs. placebo on depression (CDSS) in observed cases.
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4.1. Limitations
High attrition rates limited our statistical power to assess efﬁcacy
and safety and to identify moderators of response. The observed thera-
peutic beneﬁt of citalopram for negative symptoms is exploratory since
we did not correct the threshold of signiﬁcance for the addition of a sec-
ond primary outcome. It is also of uncertain clinical signiﬁcance since
we did not observe a change in global outcome measures. Our assess-
ment of antidepressant efﬁcacy was limited to the treatment of mild-
to-moderate symptoms at baseline and our assessment of citalopram's
efﬁcacy in the prevention of clinically signiﬁcant depressionwas limited
by the low incidence of new onset depression during the 52 week trial.
The small but statistically signiﬁcant greater improvement in depres-
sion associated with placebo is unlikely to be of clinical signiﬁcance. Fi-
nally, replication with a larger sample is needed to establish safety and
efﬁcacy of citalopram in FES.
5. Conclusion
In FES patients stabilized on antipsychotic medication for
4–24 weeks and no greater than moderate depressive symptoms at
baseline, add-on citalopram was associated with greater improvement
of negative symptoms, especially in participants with longDUP. Placebo
was associated with greater improvement in depression but this effect
was small and of uncertain clinical signiﬁcance. Rates of new-onset de-
pressionwere too low to assess a role for citalopram in theprevention of
depressive episodes. Citalopram was well-tolerated, except for sexual
side effects.
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